SynthesisBMC cardiovascular disorders2026
The effect of olanzapine on lipid profiles in humans: a time and dose response meta-analysis of randomized controlled trials.
Synthesis in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimOlanzapine, a widely used second-generation antipsychotic, is associated with notable metabolic side effects, particularly dyslipidemia. However, the extent, timing, and dose-dependence of these lipid alterations remain inadequately defined. This meta-analysis aimed to quantify the effects of olanzapine on lipid profiles in humans and to evaluate how dosage and treatment duration influence these changes.
methodsA systematic search of Scopus, Web of Science, Embase, and PubMed/MEDLINE was conducted to identify randomized controlled trials (RCTs) published up to December 1, 2025. Studies were eligible if they reported lipid outcomes (triglycerides [TG], total cholesterol [TC], high-density lipoprotein cholesterol [HDL-C], and low-density lipoprotein cholesterol [LDL-C]) before and after olanzapine treatment. Pooled weighted mean differences (WMDs) with 95% confidence intervals (CIs) were calculated using a random-effects model. Subgroup, dose-response, and sensitivity analyses were performed to explore sources of heterogeneity and assess result robustness.
resultsSeventeen trials were included. Olanzapine significantly increased TG (WMD: 24.96 mg/dL), TC (WMD: 6.57 mg/dL), and LDL-C (WMD: 4.30 mg/dL), while HDL-C decreased non-significantly (WMD: - 1.33 mg/dL). Subgroup analyses revealed that lipid alterations were more pronounced with higher doses (≥ 10 mg/day), shorter treatment durations (< 12 weeks), and in individuals with baseline body mass index (BMI) < 25 kg/m². Dose-response analysis showed a positive correlation between olanzapine dose and increases in TG and TC, and a negative correlation with HDL-C. Sensitivity analyses confirmed the robustness of findings, and no publication bias was detected for TG or HDL-C.
conclusionOlanzapine treatment is associated with a distinct dyslipidemic profile, characterized by increased TG, TC, and LDL-C and reduced HDL-C, particularly at higher doses and during early treatment. These findings underscore the need for proactive lipid monitoring and cardiovascular risk assessment, especially in patients with low baseline BMI, who appear more susceptible to rapid lipid alterations, and in those with existing metabolic risk factors or multiple cardiometabolic comorbidities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.